News & Updates
Filter by Specialty:
Is nintedanib safe, effective in patients with early-stage IPF?
Results of nintedanib use in patients with early-stage idiopathic pulmonary fibrosis (IPF) show a stable change in forced vital capacity (FVC) and a gradual decline in diffusing capacity of the lungs for carbon monoxide (DLCO) at week 52, according to an ongoing study presented at APSR 2023. In addition, treatment discontinuation is comparable to that in previous clinical trials.
Is nintedanib safe, effective in patients with early-stage IPF?
24 Nov 2023
Novel tri-agonist confers significant gains for MASLD patients
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
HBV vaccine improves survival of patients with chronic liver disease
Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.
HBV vaccine improves survival of patients with chronic liver disease
22 Nov 2023
Modified PDT on par with isotretinoin therapy for moderate-to-severe acne vulgaris
The modified red light 5-aminolevulinic acid photodynamic therapy (M-PDT) delivers a faster onset of improvement, similar overall efficacy, good tolerability, and comparable durability of response when compared with low-dose isotretinoin (ISO) therapy in patients with moderate-to-severe acne vulgaris, reports a study.